Table 1. Odds ratio (OR) and 95% confidence intervals (CI) for residual disease six months after cryotherapy (cryo) for CIN2/3 by selected pre-treatment characteristics.1Kenya, 79 HIV-positive women.
| Pre-cryocharacteristics | Total N | Cured(≤LSIL/CIN1)n (%) | Residualdisease(CIN2/3)n (%) | OR2(95% CI) | OR3(95% CI) |
| Total | 79 | 61 (77.2) | 18 (22.8) | ||
| Age | |||||
| <35 | 19 | 17 (89.5) | 2 (10.5) | 1 | 1 |
| 35–44 | 39 | 28 (71.8) | 11 (28.2) | 3.3 (0.7–16.9) | 3.3 (0.6–19.4) |
| ≥45 | 21 | 16 (76.2) | 5 (23.8) | 2.7 (0.5–15.7) | 2.2 (0.3–14.7) |
| χ 2 1 for trend | p = 0.340 | p = 0.543 | |||
| Parity | |||||
| 0–1 | 21 | 19 (90.5) | 2 (9.5) | 1 | |
| 2 | 23 | 18 (78.3) | 5 (21.7) | 2.2 (0.4–13.6) | |
| ≥3 | 35 | 24 (68.6) | 11 (31.4) | 3.5 (0.6–19.8) | |
| χ 2 1 for trend | p = 0.153 | ||||
| CD4 cells/µL at baseline | |||||
| >500 | 16 | 12 (75.0) | 4 (25.0) | 1 | |
| 200–500 | 45 | 35 (77.8) | 10 (22.2) | 1.0 (0.3–4.0) | |
| <200 | 18 | 14 (77.8) | 4 (22.2) | 1.1 (0.2–6.0) | |
| χ 2 1 for trend | p = 0.891 | ||||
| CD4 count/µL at 6-month follow-up | |||||
| ≥500 | 22 | 16 (72.7) | 6 (27.3) | 1.0 | |
| 200–500 | 47 | 37 (78.7) | 10 (21.3) | 0.7 (0.2–2.6) | |
| <200 | 10 | 8 (80.0) | 2 (20.0) | 0.8 (0.1–5.9) | |
| χ2 1 for trend | p = 0.750 | ||||
| cART | |||||
| No | 18 | 16 (88.9) | 2 (11.1) | 1 | |
| <2 years | 37 | 28 (75.7) | 9 (24.3) | 2.1 (0.4–11.7) | |
| ≥2 years | 24 | 17 (70.8) | 7 (29.2) | 2.5 (0.4–15.3) | |
| χ 2 1 for trend | p = 0.343 | ||||
| VIA | |||||
| Neg | 33 | 28 (84.9) | 5 (15.2) | 1 | |
| Pos | 46 | 33 (71.7) | 13 (28.3) | 2.6 (0.8–8.6) | |
| Cytology 4 | |||||
| Normal/ASCUS/LSIL | 25 | 23 (92.0) | 2 (8.0) | 1 | |
| HSIL or worse | 52 | 36 (69.2) | 16 (30.8) | 5.2 (1.1–25.0) | |
| Histology | |||||
| CIN2 | 45 | 40 (88.9) | 5 (11.1) | 1 | 1 |
| CIN3 | 34 | 21 (61.8) | 13 (38.2) | 5.3 (1.6–17.4) | 4.3 (1.2–15.0) |
| hrHPV (cells) | |||||
| Neg | 18 | 18 (100) | 0 | 1 | |
| Pos | 61 | 43 (70.5) | 18 (29.5) | ∞ (1.9 - ∞) | |
| HPV16 (cells) | |||||
| Neg | 64 | 53 (82.8) | 11 (17.2) | 1 | 1 |
| Pos | 15 | 8 (53.3) | 7 (46.7) | 3.9 (1.1–13.1) | 2.2 (0.6–8.1) |
| Multiple hrHPV 5 (cells) | |||||
| No | 38 | 25 (65.8) | 13 (34.2) | 1 | |
| Yes | 23 | 18 (78.3) | 5 (21.7) | 0.6 (0.2–1.9) |
1
Unless otherwise specified;
2
Adjusted for age as appropriate;
3
Among 61 hrHPV-positive women only. Adjusted for age, histology and HPV16 as appropriate;
4
Do not add up to the total because of 2 indeterminate cytology results;
5
Among hrHPV-positive women only.
cART, combination antiretroviral therapy; VIA, visual inspection with acetic acid; hrHPV, high-risk human papillomavirus; ASCUS, atypical squamous cells of undetermined significance; LSIL, low-grade squamous intraepithelial lesion; CIN, cervical intraepithelial neoplasia.